http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 08 Oct 2026 05:37:54 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Johnson+%26+Johnson+%28JNJ%29+call+put+ratio+1.6+calls+to+1+put+into+quarter+results/27162833.html <p>Johnson & Johnson (NYSE: JNJ) October 257.50 straddle priced for a move of 3.5%. Call put ratio 1.6 calls to 1 put into the expected release of quarter results before the bell on October 13.</p> http://www.streetinsider.com/Options/Johnson+%26+Johnson+%28JNJ%29+call+put+ratio+1.6+calls+to+1+put+into+quarter+results/27162833.html Thu, 08 Oct 2026 05:37:54 -0400 JNJ http://www.streetinsider.com/Press+Releases/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html <p><strong>NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson &amp; Johnson, and Genmab and AbbVie</strong></p><p>DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=u-X_XOcuv_nHd8wQKQzsJF0r9k-v9QwY2u4HJ5_0EshfXVEkDAiOMHN56WOQLFenfEQlCexigSlhhBWItIsfYNxANKsC6bVBV-WSmsaJ8RY=" rel="nofollow" target="_blank"><strong>www.247marketnews.com</strong></a>) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?</p> <p>A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These http://www.streetinsider.com/Press+Releases/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html Wed, 07 Oct 2026 09:59:58 -0400 JNJ MRK MRNA NTHI http://www.streetinsider.com/Globe+Newswire/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html <p><strong>NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson &amp; Johnson, and Genmab and AbbVie</strong></p><p>DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=u-X_XOcuv_nHd8wQKQzsJF0r9k-v9QwY2u4HJ5_0EshfXVEkDAiOMHN56WOQLFenfEQlCexigSlhhBWItIsfYNxANKsC6bVBV-WSmsaJ8RY=" rel="nofollow" target="_blank"><strong>www.247marketnews.com</strong></a>) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?</p> <p>A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These http://www.streetinsider.com/Globe+Newswire/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html Wed, 07 Oct 2026 09:59:58 -0400 JNJ MRK MRNA NTHI http://www.streetinsider.com/Press+Releases/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html <p><strong>NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson &amp; Johnson, and Genmab and AbbVie</strong></p><p>DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=u-X_XOcuv_nHd8wQKQzsJF0r9k-v9QwY2u4HJ5_0EshfXVEkDAiOMHN56WOQLFenfEQlCexigSlhhBWItIsfYNxANKsC6bVBV-WSmsaJ8RY=" rel="nofollow" target="_blank"><strong>www.247marketnews.com</strong></a>) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?</p> <p>A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These http://www.streetinsider.com/Press+Releases/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html Wed, 07 Oct 2026 09:59:58 -0400 JNJ MRK MRNA NTHI http://www.streetinsider.com/Globe+Newswire/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html <p><strong>NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson &amp; Johnson, and Genmab and AbbVie</strong></p><p>DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=u-X_XOcuv_nHd8wQKQzsJF0r9k-v9QwY2u4HJ5_0EshfXVEkDAiOMHN56WOQLFenfEQlCexigSlhhBWItIsfYNxANKsC6bVBV-WSmsaJ8RY=" rel="nofollow" target="_blank"><strong>www.247marketnews.com</strong></a>) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?</p> <p>A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These http://www.streetinsider.com/Globe+Newswire/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html Wed, 07 Oct 2026 09:59:58 -0400 JNJ MRK MRNA NTHI http://www.streetinsider.com/Press+Releases/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html <p><strong>NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson &amp; Johnson, and Genmab and AbbVie</strong></p><p>DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=u-X_XOcuv_nHd8wQKQzsJF0r9k-v9QwY2u4HJ5_0EshfXVEkDAiOMHN56WOQLFenfEQlCexigSlhhBWItIsfYNxANKsC6bVBV-WSmsaJ8RY=" rel="nofollow" target="_blank"><strong>www.247marketnews.com</strong></a>) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?</p> <p>A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These http://www.streetinsider.com/Press+Releases/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html Wed, 07 Oct 2026 09:59:58 -0400 JNJ MRK MRNA NTHI http://www.streetinsider.com/Globe+Newswire/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html <p><strong>NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson &amp; Johnson, and Genmab and AbbVie</strong></p><p>DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=u-X_XOcuv_nHd8wQKQzsJF0r9k-v9QwY2u4HJ5_0EshfXVEkDAiOMHN56WOQLFenfEQlCexigSlhhBWItIsfYNxANKsC6bVBV-WSmsaJ8RY=" rel="nofollow" target="_blank"><strong>www.247marketnews.com</strong></a>) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?</p> <p>A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These http://www.streetinsider.com/Globe+Newswire/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html Wed, 07 Oct 2026 09:59:58 -0400 JNJ MRK MRNA NTHI http://www.streetinsider.com/Press+Releases/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html <p><strong>NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson &amp; Johnson, and Genmab and AbbVie</strong></p><p>DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=u-X_XOcuv_nHd8wQKQzsJF0r9k-v9QwY2u4HJ5_0EshfXVEkDAiOMHN56WOQLFenfEQlCexigSlhhBWItIsfYNxANKsC6bVBV-WSmsaJ8RY=" rel="nofollow" target="_blank"><strong>www.247marketnews.com</strong></a>) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?</p> <p>A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These http://www.streetinsider.com/Press+Releases/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html Wed, 07 Oct 2026 09:59:58 -0400 JNJ MRK MRNA NTHI http://www.streetinsider.com/Globe+Newswire/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html <p><strong>NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson &amp; Johnson, and Genmab and AbbVie</strong></p><p>DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=u-X_XOcuv_nHd8wQKQzsJF0r9k-v9QwY2u4HJ5_0EshfXVEkDAiOMHN56WOQLFenfEQlCexigSlhhBWItIsfYNxANKsC6bVBV-WSmsaJ8RY=" rel="nofollow" target="_blank"><strong>www.247marketnews.com</strong></a>) -- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time?</p> <p>A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These http://www.streetinsider.com/Globe+Newswire/2026+Takes+a+Promising+Turn+in+the+Fight+Against+Cancer+as+Five+Advances+Offer+New+Hope/27159280.html Wed, 07 Oct 2026 09:59:58 -0400 JNJ MRK MRNA NTHI http://www.streetinsider.com/Analyst+Comments/Guggenheim+Reiterates+Buy+Rating+on+Johnson+%26+Johnson+%28JNJ%29/27157987.html <p>Guggenheim analyst Vamil Divan reiterated a Buy rating and $287.00 price target on Johnson & Johnson (NYSE: JNJ).</p><p>The analyst commented: "JNJ will kick off 3Q 2026 earnings for our large cap biopharma group on Tues Oct 13 (link to 8:30am ET webcast here). Ahead of the quarter, we are updating our JNJ model following our review of the latest prescription data, company news, and management commentary since JNJ's 2Q 2026 call in July. Overall, we expect JNJ to deliver 3Q 2026 revenues and earnings roughly in line with current FactSet consensus estimates (Gugg revenues at $25.49Bn vs. consensus at $25.37Bn, http://www.streetinsider.com/Analyst+Comments/Guggenheim+Reiterates+Buy+Rating+on+Johnson+%26+Johnson+%28JNJ%29/27157987.html Wed, 07 Oct 2026 07:30:09 -0400 JNJ http://www.streetinsider.com/Analyst+PT+Change/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%24290+at+RBC+Capital/27151135.html <p>RBC Capital analyst Shagun Singh raised the price target on Johnson & Johnson (NYSE: JNJ) to $290.00 (from $287.00) while maintaining a Outperform rating.</p><p>The analyst comments "We raise our PT to $290 from $287. For 3Q26, we are 1% ahead on sales driven by Pharma (1.3% ahead anchored by Tremfya/Icotyde sales) and in-line on Medtech, but we note competitive pressures and persistent geopolitical headwinds, most pronounced in electrophysiology. However, on EPS we are 9% below ($2.55/share vs. cons. $2.81/share) impacted by the closing of Firefly and Sail in 3Q26, not fully reflected in consensus (FY guidance now $10.96-$11.11; midpoint of http://www.streetinsider.com/Analyst+PT+Change/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%24290+at+RBC+Capital/27151135.html Tue, 06 Oct 2026 05:59:05 -0400 JNJ http://www.streetinsider.com/Analyst+Comments/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%24290+at+RBC+Capital/27151135.html <p>RBC Capital analyst Shagun Singh raised the price target on Johnson & Johnson (NYSE: JNJ) to $290.00 (from $287.00) while maintaining a Outperform rating.</p><p>The analyst comments "We raise our PT to $290 from $287. For 3Q26, we are 1% ahead on sales driven by Pharma (1.3% ahead anchored by Tremfya/Icotyde sales) and in-line on Medtech, but we note competitive pressures and persistent geopolitical headwinds, most pronounced in electrophysiology. However, on EPS we are 9% below ($2.55/share vs. cons. $2.81/share) impacted by the closing of Firefly and Sail in 3Q26, not fully reflected in consensus (FY guidance now $10.96-$11.11; midpoint of http://www.streetinsider.com/Analyst+Comments/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%24290+at+RBC+Capital/27151135.html Tue, 06 Oct 2026 05:59:05 -0400 JNJ http://www.streetinsider.com/Corporate+News/J%26J+releases+2-year+icotrokinra+data+for+hard-to-treat+plaque+psoriasis/27138428.html <p>Johnson & Johnson (NYSE: JNJ) released two-year data from its Phase 3 ICONIC-TOTAL study of ICOTYDE (icotrokinra) in patients with plaque psoriasis affecting sensitive body areas, presenting the findings at the European Academy of Dermatology and Venereology Congress 2026.</p><p>According to the company's press release, 70% of treated patients achieved clear or almost clear skin at Week 112, up from 57% at Week 16. Among patients with site-specific disease, 60% with scalp psoriasis and 89% with genital psoriasis achieved complete skin clearance at Week 112. Patients with hand and/or foot psoriasis showed a 63% complete clearance rate at the same time http://www.streetinsider.com/Corporate+News/J%26J+releases+2-year+icotrokinra+data+for+hard-to-treat+plaque+psoriasis/27138428.html Fri, 02 Oct 2026 06:03:10 -0400 JNJ http://www.streetinsider.com/FDA/J%26J+releases+2-year+icotrokinra+data+for+hard-to-treat+plaque+psoriasis/27138428.html <p>Johnson & Johnson (NYSE: JNJ) released two-year data from its Phase 3 ICONIC-TOTAL study of ICOTYDE (icotrokinra) in patients with plaque psoriasis affecting sensitive body areas, presenting the findings at the European Academy of Dermatology and Venereology Congress 2026.</p><p>According to the company's press release, 70% of treated patients achieved clear or almost clear skin at Week 112, up from 57% at Week 16. Among patients with site-specific disease, 60% with scalp psoriasis and 89% with genital psoriasis achieved complete skin clearance at Week 112. Patients with hand and/or foot psoriasis showed a 63% complete clearance rate at the same time http://www.streetinsider.com/FDA/J%26J+releases+2-year+icotrokinra+data+for+hard-to-treat+plaque+psoriasis/27138428.html Fri, 02 Oct 2026 06:03:10 -0400 JNJ http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+announces+new+ICOTYDE%C2%AE+%28icotrokinra%29+data+in+difficult-to-treat+plaque+psoriasis+with+proven+durability+through+2-years%2C+affirming+its+use+as+a+powerful+first+line+systemic+ther/27138262.html <div class="xn-content"> <ul type="disc"> <li><i>Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body</i></li> <li><i>60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112</i></li> http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+announces+new+ICOTYDE%C2%AE+%28icotrokinra%29+data+in+difficult-to-treat+plaque+psoriasis+with+proven+durability+through+2-years%2C+affirming+its+use+as+a+powerful+first+line+systemic+ther/27138262.html Fri, 02 Oct 2026 06:00:00 -0400 JNJ http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+announces+new+ICOTYDE%C2%AE+%28icotrokinra%29+data+in+difficult-to-treat+plaque+psoriasis+with+proven+durability+through+2-years%2C+affirming+its+use+as+a+powerful+first+line+systemic+ther/27138262.html <div class="xn-content"> <ul type="disc"> <li><i>Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body</i></li> <li><i>60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112</i></li> http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+announces+new+ICOTYDE%C2%AE+%28icotrokinra%29+data+in+difficult-to-treat+plaque+psoriasis+with+proven+durability+through+2-years%2C+affirming+its+use+as+a+powerful+first+line+systemic+ther/27138262.html Fri, 02 Oct 2026 06:00:00 -0400 JNJ http://www.streetinsider.com/Press+Releases/New+Global+Survey+by+Johnson+%26amp%3B+Johnson+Finds+Most+Women+Don%E2%80%99t+Connect+Eye+Health+Changes+with+Menopause/27131646.html <p class="bwalignc"> <i>Johnson &amp; Johnson, Naomi Watts and the American Optometric Association encourage women to make eye health part of midlife care</i> </p> <p> JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Johnson &amp; Johnson (NYSE: JNJ) today released new findings that show most women know menopause can affect mood and sleep, but fewer than half realize their eye health may change too. A new global survey of 6,000 women found that only 40% connect eye changes with the menopause transition—even though 90% say seeing clearly and comfortably helps them feel confident, capable or like themselves.i </p><p id="news-body-cta">This press release features multimedia. View the full release here: http://www.streetinsider.com/Press+Releases/New+Global+Survey+by+Johnson+%26amp%3B+Johnson+Finds+Most+Women+Don%E2%80%99t+Connect+Eye+Health+Changes+with+Menopause/27131646.html Thu, 01 Oct 2026 07:45:00 -0400 JNJ http://www.streetinsider.com/Business+Wire/New+Global+Survey+by+Johnson+%26amp%3B+Johnson+Finds+Most+Women+Don%E2%80%99t+Connect+Eye+Health+Changes+with+Menopause/27131646.html <p class="bwalignc"> <i>Johnson &amp; Johnson, Naomi Watts and the American Optometric Association encourage women to make eye health part of midlife care</i> </p> <p> JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Johnson &amp; Johnson (NYSE: JNJ) today released new findings that show most women know menopause can affect mood and sleep, but fewer than half realize their eye health may change too. A new global survey of 6,000 women found that only 40% connect eye changes with the menopause transition—even though 90% say seeing clearly and comfortably helps them feel confident, capable or like themselves.i </p><p id="news-body-cta">This press release features multimedia. View the full release here: http://www.streetinsider.com/Business+Wire/New+Global+Survey+by+Johnson+%26amp%3B+Johnson+Finds+Most+Women+Don%E2%80%99t+Connect+Eye+Health+Changes+with+Menopause/27131646.html Thu, 01 Oct 2026 07:45:00 -0400 JNJ http://www.streetinsider.com/Analyst+PT+Change/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%2413+at+JPMorgan/27118179.html JPMorgan analyst Chris Schott raised the price target on Johnson & Johnson (NYSE: JNJ) to $13.00 (from $6.00) while maintaining a Neutral rating. http://www.streetinsider.com/Analyst+PT+Change/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%2413+at+JPMorgan/27118179.html Tue, 29 Sep 2026 08:41:50 -0400 JNJ http://www.streetinsider.com/Corporate+News/J%26J+presents+two-year+IMAAVY+data+in+adolescent+myasthenia+gravis/27117850.html <p>Johnson & Johnson (NYSE: JNJ) announced new data on IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis (gMG), including two-year results from a Phase 2/3 adolescent study, to be presented at the 2026 Myasthenia Gravis Foundation of America Scientific Session and American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.</p><p>The Vibrance-MG Phase 2/3 long-term extension study enrolled seven adolescents aged 12-17 with anti-acetylcholine receptor positive gMG. At Week 108, participants showed mean changes from baseline of -2.88 points on the Myasthenia Gravis Activities of Daily Living scale and -8.25 points on the Quantitative Myasthenia Gravis scale, consistent with results measured at Week http://www.streetinsider.com/Corporate+News/J%26J+presents+two-year+IMAAVY+data+in+adolescent+myasthenia+gravis/27117850.html Tue, 29 Sep 2026 08:05:09 -0400 JNJ http://www.streetinsider.com/FDA/J%26J+presents+two-year+IMAAVY+data+in+adolescent+myasthenia+gravis/27117850.html <p>Johnson & Johnson (NYSE: JNJ) announced new data on IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis (gMG), including two-year results from a Phase 2/3 adolescent study, to be presented at the 2026 Myasthenia Gravis Foundation of America Scientific Session and American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.</p><p>The Vibrance-MG Phase 2/3 long-term extension study enrolled seven adolescents aged 12-17 with anti-acetylcholine receptor positive gMG. At Week 108, participants showed mean changes from baseline of -2.88 points on the Myasthenia Gravis Activities of Daily Living scale and -8.25 points on the Quantitative Myasthenia Gravis scale, consistent with results measured at Week http://www.streetinsider.com/FDA/J%26J+presents+two-year+IMAAVY+data+in+adolescent+myasthenia+gravis/27117850.html Tue, 29 Sep 2026 08:05:09 -0400 JNJ http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+presents+new+data+reinforcing+sustained+disease+control+and+improved+daily+function+achieved+with+IMAAVY%C2%AE+%28nipocalimab-aahu%29+in+generalized+myasthenia+gravis+%28gMG%29/27117830.html <div class="xn-content"> <ul type="disc"> <li><i>New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in </i><i>anti-AChR+^a </i><i>adolescents</i></li> <li><i>Retrospective survey in adults identified fluctuating symptom control as a top driver for discontinuing prior advanced http://www.streetinsider.com/Press+Releases/Johnson+%26amp%3B+Johnson+presents+new+data+reinforcing+sustained+disease+control+and+improved+daily+function+achieved+with+IMAAVY%C2%AE+%28nipocalimab-aahu%29+in+generalized+myasthenia+gravis+%28gMG%29/27117830.html Tue, 29 Sep 2026 08:03:00 -0400 JNJ http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+presents+new+data+reinforcing+sustained+disease+control+and+improved+daily+function+achieved+with+IMAAVY%C2%AE+%28nipocalimab-aahu%29+in+generalized+myasthenia+gravis+%28gMG%29/27117830.html <div class="xn-content"> <ul type="disc"> <li><i>New two-year findings from the Phase 2/3 long-term extension demonstrate sustained disease control through two years, improvement in daily function and muscle strength, and reductions in corticosteroid use in </i><i>anti-AChR+^a </i><i>adolescents</i></li> <li><i>Retrospective survey in adults identified fluctuating symptom control as a top driver for discontinuing prior advanced http://www.streetinsider.com/PRNewswire/Johnson+%26amp%3B+Johnson+presents+new+data+reinforcing+sustained+disease+control+and+improved+daily+function+achieved+with+IMAAVY%C2%AE+%28nipocalimab-aahu%29+in+generalized+myasthenia+gravis+%28gMG%29/27117830.html Tue, 29 Sep 2026 08:03:00 -0400 JNJ http://www.streetinsider.com/Analyst+PT+Change/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%24278+at+BofA+Securities/27116424.html <p>BofA Securities analyst Jason M. Gerberry raised the price target on Johnson & Johnson (NYSE: JNJ) to $278.00 (from $263.00) while maintaining a Neutral rating.</p><p>The analyst comments "We raise our Icotyde forecasts and update our JNJ model for recent IPR&D; with limited script/sales data in hand, we make minimal changes to FY26 sales forecasts. We forecast 3QE $25.5bn sales and $2.53 EPS, in-line with consensus sales and (12%) below on EPS. JNJ disclosed IPR&D $0.64 EPS dilution for 2026, mostly realized in 3Q (below) and cons may not fully reflect that impact. We model +6% Y/Y revenue growth at the http://www.streetinsider.com/Analyst+PT+Change/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%24278+at+BofA+Securities/27116424.html Tue, 29 Sep 2026 05:28:27 -0400 JNJ http://www.streetinsider.com/Analyst+Comments/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%24278+at+BofA+Securities/27116424.html <p>BofA Securities analyst Jason M. Gerberry raised the price target on Johnson & Johnson (NYSE: JNJ) to $278.00 (from $263.00) while maintaining a Neutral rating.</p><p>The analyst comments "We raise our Icotyde forecasts and update our JNJ model for recent IPR&D; with limited script/sales data in hand, we make minimal changes to FY26 sales forecasts. We forecast 3QE $25.5bn sales and $2.53 EPS, in-line with consensus sales and (12%) below on EPS. JNJ disclosed IPR&D $0.64 EPS dilution for 2026, mostly realized in 3Q (below) and cons may not fully reflect that impact. We model +6% Y/Y revenue growth at the http://www.streetinsider.com/Analyst+Comments/Johnson+%26+Johnson+%28JNJ%29+PT+Raised+to+%24278+at+BofA+Securities/27116424.html Tue, 29 Sep 2026 05:28:27 -0400 JNJ